Anthem Biosciences

ANTHEM

Q: How strong is Anthem Biosciences balance sheet?

Balance sheet of Anthem Biosciences is strong.It shouldn't have solvency or liquidity issues.

Q: Is the debt of Anthem Biosciences increasing or decreasing?

The net debt of Anthem Biosciences is decreasing.Latest net debt of Anthem Biosciences is -₹525 Crs as of Mar-25.This is less than Mar-24 when it was -₹136.19 Crs.

Q: Is Anthem Biosciences stock expensive?

There is insufficient historical data to gauge this.Latest PE of Anthem Biosciences is 96.1

Price

Mid Cap

₹42,609 Cr.

New to Zerodha? Sign-up for free.

Anthem Biosciences, India’s fastest-growing CRDMO, offers end-to-end drug discovery, development, and manufacturing services across small molecules and biologics, serving global biotech and pharma firms with advanced, innovation-driven solutions.

Anthem Biosciences, India’s fastest-growing CRDMO, offers end-to-end drug discovery, development, a… More

Low

702

52W Range

High

802

94.42

Sector PE

28.86

P/B

17.68

Div.Yield

ROE

18.73%

EBIDTA

ROCE

27.09

EPS

New to Zerodha? Sign-up for free.

Share Price
Financials
Revenue mix
Shareholdings
Peers
Forensics

This data is currently unavailable for this company.

Summary
Profit & Loss
Balance sheet
Cashflow

View Detailed Summary

This data is currently unavailable for this company.

Yearly | Quarterly

(In Cr.)

(In Cr.)
This data is currently unavailable for this company.

Financial Ratio's

(In %)

Detailed P&L Report

(In Cr.)

Detailed Balance Sheet

Financial Year (In Cr.)

Detailed Cash Flow

Product wise
Location wise

ANTHEM
Revenue Mix

Latest

Historic

This data is currently unavailable for this company.

ANTHEM
Revenue Mix

Latest

Historic

This data is currently unavailable for this company.

More Info

Shareholdings

Holders

Detailed Shareholdings

This data is currently unavailable for this company.

Peers

Detailed Peers

Forensics

View Detailed Forensics

Recent events

News
Corporate Actions

India's Anthem BioSciences jumps in trading debut

Jul 21, 2025

This data is currently unavailable for this company.

More Mid Cap Ideas

See similar 'Mid' cap companies with recent activity

Promoter Buying

Companies where the promoters are bullish

Detailed List

Capex

Companies investing on expansion

Detailed List

Superstar Investor

Companies where well known investors have invested

Detailed List

Popular questions

Business
Financials
Share Price
Shareholdings

What does Anthem Biosciences do?

Anthem Biosciences is an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing with integrated New Chemical Entity (NCE) and New Biological Entity (NBE) capabilities across drug discovery, development, and commercial manufacturing.

Who are the competitors of Anthem Biosciences?

Anthem Biosciences major competitors are Syngene Internation., Sai Life Sciences, Cohance Lifesciences, Akums Drugs & Pharma, Divi's Lab. Market Cap of Anthem Biosciences is ₹43,365 Crs. While the median market cap of its peers are ₹29,096 Crs.

Is Anthem Biosciences financially stable compared to its competitors?

Anthem Biosciences seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

Does Anthem Biosciences pay decent dividends?

The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Anthem Biosciences latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

How has Anthem Biosciences allocated its funds?

Companies resources are allocated to majorly productive assets like Plant & Machinery

How strong is Anthem Biosciences balance sheet?

Balance sheet of Anthem Biosciences is strong. It shouldn't have solvency or liquidity issues.

Is the profitablity of Anthem Biosciences improving?

The profit is oscillating. The profit of Anthem Biosciences is ₹451 Crs for Mar 2025, ₹367 Crs for Mar 2024 and ₹385 Crs for Mar 2023

Is the debt of Anthem Biosciences increasing or decreasing?

The net debt of Anthem Biosciences is decreasing. Latest net debt of Anthem Biosciences is -₹525 Crs as of Mar-25. This is less than Mar-24 when it was -₹136.19 Crs.

Is Anthem Biosciences stock expensive?

There is insufficient historical data to gauge this. Latest PE of Anthem Biosciences is 96.1

Has the share price of Anthem Biosciences grown faster than its competition?

There is not enough historical data for the companies share price.

Is the promoter bullish about Anthem Biosciences?

There is Insufficient data to gauge this.

Are mutual funds buying/selling Anthem Biosciences?

There is Insufficient data to gauge this.

ANTHEM

Share Price

Financials

Revenue mix

Shareholdings

Peers

Forensics

Summary

Profit & Loss

Balance sheet

Cashflow

Product wise

Location wise

Recent events

News

Corporate Actions

India's Anthem BioSciences jumps in trading debut

More Mid Cap Ideas

Promoter Buying

Capex

Superstar Investor

Popular questions

Business

Financials

Share Price

Shareholdings

What does Anthem Biosciences do?

Who are the competitors of Anthem Biosciences?

Is Anthem Biosciences financially stable compared to its competitors?

Does Anthem Biosciences pay decent dividends?

How has Anthem Biosciences allocated its funds?

How strong is Anthem Biosciences balance sheet?

Is the profitablity of Anthem Biosciences improving?

Is the debt of Anthem Biosciences increasing or decreasing?

Is Anthem Biosciences stock expensive?

Has the share price of Anthem Biosciences grown faster than its competition?

Is the promoter bullish about Anthem Biosciences?

Are mutual funds buying/selling Anthem Biosciences?